AllazoHealth Wins 2017 FiercePharma Innovation Award for its Artificial Intelligence-Powered Medication Adherence Solution

“Our product is the only AI platform to be validated to optimize medication adherence programs by a double-blinded, randomized controlled study.”

“We are pleased to be recognized by Fierce for our leadership in making medication adherence programs smarter and more effective,” said Clifford Jones, CEO and Founder of AllazoHealth. “Our product is the only AI platform to be validated to optimize medication adherence programs by a double-blinded, randomized controlled study. As a result, we are gaining substantial traction with pharma manufacturers, payers, and retail pharmacies who seek to increase growth and brand value in an increasingly competitive market environment.”

Studies have shown that the reasons for non-adherence are a complex mix of situational and behavioral barriers that are unique to each patient. However, traditional adherence programs that use rules-based triggers or historical data to target interventions fail to effectively consider the nuances of each patient. “This is both very expensive and highly inefficient,” said Jones. “AllazoHealth is different because we’re not just another intervention services provider with a new tool. As the “upstream brains,” we optimize our clients’ existing adherence programs by determining exactly who should receive interventions and when. This substantially reduces unnecessary spend and ensures that patients are engaged in the most meaningful way to increase adherence rates as much as possible.”

By using the AI platform to predict and identify at-risk patients and then target interventions in message and timing, the AllazoEngine achieves a 5.5x greater adherence uplift compared to traditional programs. These results were validated last year in a randomized…

Article Source…

Leave a Reply

Your email address will not be published. Required fields are marked *